N-[2-{4-(4-(t-butoxycarbonyl)piperazin-1-yl)phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methylbenzylidene)hydrazine | 1232220-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[2-{4-(4-(t-butoxycarbonyl)piperazin-1-yl)phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methylbenzylidene)hydrazine
• 英文别名: N-[2-{4-(4-t-butoxycarbonyl-piperazin-1-yl)-phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methyl-benzylidene)-hydrazine；N-[2-{4-(4-t-butoxycarbonyl-piperazin-1-yl)phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methyl-benzylidene)hydrazine；Tert-butyl 4-[4-[5-[2-[(3-methylphenyl)methylidene]hydrazinyl]-7-morpholin-4-ylpyrazolo[1,5-a]pyrimidin-2-yl]phenyl]piperazine-1-carboxylate；tert-butyl 4-[4-[5-[2-[(3-methylphenyl)methylidene]hydrazinyl]-7-morpholin-4-ylpyrazolo[1,5-a]pyrimidin-2-yl]phenyl]piperazine-1-carboxylate
• CAS: 1232220-47-1
• 化学式: C₃₃H₄₀N₈O₃
• 分子量: 596.732
• InChiKey: GHEPZQPPWVDPIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  44
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  99.8
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  N-[2-{4-(4-(t-butoxycarbonyl)piperazin-1-yl)phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methylbenzylidene)hydrazine 在 三氟乙酸 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.33h， 生成 N-(3-methyl-benzylidene)-N'-{7-morpholin-4-yl-2-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-5-yl}-hydrazine
  参考文献：
  名称：

  PYRAZOLO-PYRIMIDINE COMPOUNDS

  摘要：

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。

  公开号：

  US20110294781A1
• 作为产物：
  描述：

  2-(4-bromophenyl)-5-chloro-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 、 溶剂黄146 sodium t-butanolate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 1.5h， 生成 N-[2-{4-(4-(t-butoxycarbonyl)piperazin-1-yl)phenyl}-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl]-N'-(3-methylbenzylidene)hydrazine
  参考文献：
  名称：

  PYRAZOLO-PYRIMIDINE COMPOUNDS

  摘要：

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。

  公开号：

  US20110294781A1

文献信息

• Structure–activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201
  作者：Nobuhiko Hayakawa、Masatsugu Noguchi、Sen Takeshita、Agung Eviryanti、Yukie Seki、Hikaru Nishio、Ryohei Yokoyama、Misato Noguchi、Manami Shuto、Yoichiro Shima、Kanna Kuribayashi、Shunsuke Kageyama、Hiroyuki Eda、Manabu Suzuki、Tomohisa Hatta、Shun-ichiro Iemura、Tohru Natsume、Itsuya Tanabe、Ryusuke Nakagawa、Makoto Shiozaki、Kuniya Sakurai、Masataka Shoji、Ayatoshi Andou、Takashi Yamamoto

  DOI：10.1016/j.bmc.2014.03.036

  日期：2014.6

  Interleukin-12 (IL-12) and IL-23 are proinflammatory cytokines and therapeutic targets for inflammatory and autoimmune diseases, including inflammatory bowel diseases, psoriasis, rheumatoid arthritis, and multiple sclerosis. We describe the discovery of APY0201, a unique small molecular IL-12/23 production inhibitor, from activated macrophages and monocytes, and demonstrate ameliorated inflammation in an experimental model of colitis. Through a chemical proteomics approach using a highly sensitive direct nanoflow LC-MS/MS system and bait compounds equipped with the FLAG epitope associated regulator of PIKfyve (ArPIKfyve) was detected. Further study identified its associated protein phosphoinositide kinase, FYVE finger-containing (PIKfyve), as the target protein of APY0201, which was characterized as a potent, highly selective, ATP-competitive PIKfyve inhibitor that interrupts the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(3,5)P-2. These results elucidate the function of PIKfyve kinase in the IL-12/23 production pathway and in IL-12/23-driven inflammatory disease pathologies to provide a compelling rationale for targeting PIKfyve kinase in inflammatory and autoimmune diseases. (C) 2014 Elsevier Ltd. All rights reserved.
• PYRAZOLO-PYRIMIDINE COMPOUNDS
  申请人：YAMAMOTO Takashi

  公开号：US20110294781A1

  公开（公告）日：2011-12-01

  The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。